Search

everythinglearnresearchcommunity

for

Search:↓

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

New treatments are needed for non-scarring alopecia due to current limitations.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Oral tofacitinib successfully treated total body hair loss in one patient.

Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.

CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.

Vitamin A affects hair loss and immune response in alopecia areata.

New treatments for COVID-19 show promise, but more effective antiviral drugs are needed.

PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.

Alopecia Areata can affect nails, often improving on its own, but JAK inhibitors may help.

Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.

Certain genetic variations in IL18 may increase the risk of alopecia areata in Koreans.

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

New treatments for alopecia areata show promise, but standardized guidelines are needed.

Inactive stem cells in hair follicles and muscles can avoid detection by the immune system.

The skin can independently form immune responses through special structures, offering new ways to treat skin diseases.

Ovalbumin–aluminum sensitization causes increased pain sensitivity and nerve changes in mice.

Cosmeceuticals like sunscreens may trigger frontal fibrosing alopecia, but more research is needed.

TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Thyroid issues can cause alopecia areata.

Advancements in diagnostics, treatments, and technology have improved hair loss detection and restoration, with some types being reversible.

SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Platelet-rich plasma therapy improves oral lichen planus symptoms with few side effects.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.

The nail matrix has a reduced immune response, protecting it from autoimmunity.